An interventional study of Acyclovir in Leukoplakia, Hairy and HIV Infections, sponsored by Glaxo Wellcome. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Not applicable, Interventional, and Treatment
Among 21 studies in AIDS-Related Complex by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. AIDS-Related Complex · GlaxoSmithKline.
Among the 21 studies in AIDS-Related Complex by GlaxoSmithKline, this one is one of 13 with no phase, and was the 1st registered.
283 studies on the registry are indexed under AIDS-Related Complex; 2 are open to participants now.
Browse AIDS-Related Complex studies →None of the 21 studies in AIDS-Related Complex by GlaxoSmithKline is open now. The open studies under AIDS-Related Complex, anywhere →
Of the 2 AIDS-Related Complex studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 288 across the 8 interventional studies. Of the 21 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Glaxo Wellcome, one of the names counted as GlaxoSmithKline. Under that name alone:
Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in AIDS-Related Complex by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.
283 studies on the registry are indexed under AIDS-Related Complex; 2 are open to participants now.
Browse AIDS-Related Complex studies →Glaxo Wellcome is the lead sponsor of 72 studies on the registry; none are open to participants now.
First submitted before Glaxo Wellcome became part of GlaxoSmithKline.
Compared within AIDS-Related Complex, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is HIV Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Concurrent Medication:
Allowed:
Patient must have:
Exclusion Criteria
Co-existing Condition:
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Concurrent Medication:
Excluded within 2 weeks of study entry:
Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded.
Prior Medication:
Excluded within 2 weeks of study entry:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in May 1990. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acyclovir